EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects

Sandra L Carroll iD, Blandine Mondésert iD, Andrew D Krahn iD, Jamil G Bashir iD, Kathryn Fisher iD, Kalpana Nair iD, Jeff S Healey iD

European Journal of Cardiovascular Nursing · 2024

DOI: 10.1093/eurjcn/zvae067 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cardiovascular Nursing, 2024. Verfasst von Sandra L Carroll und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, McMaster University, 1280 Main Street West, HSC 2J17, Hamilton, ON, Canada L8S 4K1. Hauptthemen laut MEDLINE: Quality of Life, Defibrillators, Implantable, Patient Reported Outcome Measures. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Scientific.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patient-reported outcomes (PROs) provide important insights into patients’ acceptance of their medical devices. Avoid Transvenous Leads in Appropriate Subjects (ATLAS), a randomized, multi-centre, open-label clinical trial, recently reported fewer perioperative complications in subcutaneous implantable cardioverter defibrillator (S-ICD) compared with transvenous ICD (TV-ICD) patients. This study reports PROs, including device-specific and generic quality of life (QOL), from the ATLAS trial. Methods and results Device-specific QOL was the primary PRO using the Florida Patient Acceptance Survey (FPAS) at 1 and 6 months’ post-implantation. Secondary outcomes included generic QOL using the Medical Outcomes Survey (SF-36) pre-implant and 6 months’ post-implantation. The FPAS and SF-36 were analysed using analysis of covariance. Pain measured using a Numeric Rating Scale, at 1 and 6 months, anaesthetic, body mass index, and within/between differences were analysed using descriptive statistics and mixed-effects linear models. Of the 503 patients randomized in ATLAS, 404 had complete FPAS data to be included in this analysis. Participant characteristics were balanced. There were no significant differences between S-ICD and TV-ICD for the FPAS or SF-36, across time points. Mean total FPAS scores increased from 73.73 (16.09) to 77.05 (16.13) and 74.43 (15.35) to 78.25 (15.88) for S-ICD and TV-ICD, respectively (P < 0.001). Patient-reported outcomes suggested that both devices were associated with good QOL.

Conclusion

Device-specific and generic QOL were similar between S-ICD and TV-ICD groups up to 6 months’ post-implantation, indicating that regardless of device type, both groups reported good device-specific QOL in ATLAS patients. Subcutaneous ICD patients reported higher pain scores at implant, but pain decreased by 6 months. The findings offer evidence that can be included during shared decision-making. The inclusion of patient partners in ATLAS provided an opportunity to measure PROs that were deemed important to patients. Registration ClinialTrials.gov: NCT02881255

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeDefibrillators, ImplantablePatient Reported Outcome MeasuresHumansMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

Device-specific quality of lifeImplantable cardioverter defibrillatorPatient reported outcomes

Autor:innen und Institutionen

  • School of Nursing, McMaster University, 1280 Main Street West, HSC 2J17, Hamilton, ON, Canada L8S 4K1.
  • Population Health Research Institute, 237 Barton Street East, Hamilton, ON L8L 2X2, Canada.
  • Montreal Heart Institute, 5000 Rue Bélanger, Montréal, QC H1T 1C8, Canada.
  • Division of Cardiology, University of British Columbia, 2775 Laurel St, 9th Floor, Vancouver, BC V5Z 1M9, Canada.
  • Faculty of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.

ORCID-Profile: Sandra L Carroll, Blandine Mondésert, Andrew D Krahn, Jamil G Bashir, Kathryn Fisher, Kalpana Nair, Jeff S Healey

Förderung

  • Boston Scientific

Zitieren

APA

Carroll, S. L., Mondésert, B., Krahn, A. D., Bashir, J. G., Fisher, K., Nair, K., & Healey, J. S. (2024). Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects. European Journal of Cardiovascular Nursing. https://doi.org/10.1093/eurjcn/zvae067

Vancouver

Carroll SL, Mondésert B, Krahn AD, Bashir JG, Fisher K, Nair K, et al. Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects. European Journal of Cardiovascular Nursing. 2024. doi:10.1093/eurjcn/zvae067

BibTeX
@article{Carroll2024,
  author = {Carroll, Sandra L and Mondésert, Blandine and Krahn, Andrew D and Bashir, Jamil G and Fisher, Kathryn and Nair, Kalpana and Healey, Jeff S},
  title = {Device-specific quality of life: results from the ATLAS trial—avoid transvenous leads in appropriate subjects},
  journal = {European Journal of Cardiovascular Nursing},
  year = {2024},
  doi = {10.1093/eurjcn/zvae067}
}
Kostenlos starten →